{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:10:38Z","timestamp":1795011038692,"version":"4.9.1"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0774-y","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T12:04:07Z","timestamp":1574337847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":284,"title":["Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6685-4621","authenticated-orcid":false,"given":"Houssein","family":"Safa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Anh","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa E","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E","family":"Suarez-Almazor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Fa\u2019ak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Saberian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassian","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Tummala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Woodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0153-0244","authenticated-orcid":false,"given":"Adi","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"key":"774_CR1","volume-title":"Princeton NBMS","author":"Opdivo-nivolumab [package insert]","year":"2019","unstructured":"Opdivo-nivolumab [package insert]. Princeton NBMS, 2019. \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125554s073lbl.pdf\n\n."},{"key":"774_CR2","volume-title":"Princeton NBS","author":"YERVOY-ipilimumab [package insert]","year":"2019","unstructured":"YERVOY-ipilimumab [package insert]. Princeton NBS, 2019. \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125377s102lbl.pdf\n\n."},{"key":"774_CR3","volume-title":"County Cork IM","author":"KEYTRUDA- Pembrolizumab [package insert]","year":"2019","unstructured":"KEYTRUDA- Pembrolizumab [package insert]. County Cork IM, 2019. \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125514s053lbl.pdf\n\n."},{"key":"774_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejca.2016.10.009","volume":"69","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM. Adjuvant ipilimumab in stage III melanoma: new landscape, new questions. Eur J Cancer. 2016;69:39\u201342.","journal-title":"Eur J Cancer"},{"issue":"5","key":"774_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522\u201330.","journal-title":"Lancet Oncol"},{"issue":"19","key":"774_CR6","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant Pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801.","journal-title":"N Engl J Med"},{"issue":"19","key":"774_CR7","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"Jeffrey Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Zelanoma. N Engl J Med. 2017;377(19):1824-35.","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"774_CR8","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in stage III non-small-cell lung Cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"issue":"2","key":"774_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/M17-2073","volume":"168","author":"Noha Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review. Annals of internal medicine. 2018;168(2):121-30.","journal-title":"Annals of Internal Medicine"},{"issue":"15_suppl","key":"774_CR10","doi-asserted-by":"publisher","first-page":"9019","DOI":"10.1200\/jco.2015.33.15_suppl.9019","volume":"33","author":"Douglas Buckner Johnson","year":"2015","unstructured":"Johnson DB, Khushalani NI, Puzanov I, Mudigonda T, Kaufman H, Sosman JA, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. J Clin Oncol Conf. 2015;33(15 SUPPL. 1):9019.","journal-title":"Journal of Clinical Oncology"},{"key":"774_CR11","doi-asserted-by":"crossref","unstructured":"Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong AN, Park JJ, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2016.","DOI":"10.1093\/annonc\/mdw443"},{"key":"774_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1\u20138.","journal-title":"Eur J Cancer"},{"issue":"6","key":"774_CR13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","volume":"22","author":"J Larkin","year":"2017","unstructured":"Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, et al. Neurologic serious adverse events associated with Nivolumab plus Ipilimumab or Nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22(6):709\u201318.","journal-title":"Oncologist."},{"key":"774_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","volume":"82","author":"D Makarious","year":"2017","unstructured":"Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128\u201336.","journal-title":"Eur J Cancer"},{"issue":"3","key":"774_CR15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.nmd.2017.01.002","volume":"27","author":"NL Gonzalez","year":"2017","unstructured":"Gonzalez NL, Puwanant A, Lu A, Marks SM, Zivkovic SA. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord. 2017;27(3):266\u20138.","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"774_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","volume":"18","author":"JC Kao","year":"2018","unstructured":"Kao JC, Brickshawana A, Liewluck T. Neuromuscular complications of programmed cell Death-1 (PD-1) inhibitors. Curr Neurol Neurosci Rep. 2018;18(10):63.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"774_CR17","doi-asserted-by":"crossref","first-page":"175628641879986","DOI":"10.1177\/1756286418799864","volume":"11","author":"MC Dalakas","year":"2018","unstructured":"Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system. Ther Adv Neurol Disord. 2018;11:1756286418799864.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"774_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/mus.26070","volume":"58","author":"Noah A. Kolb","year":"2018","unstructured":"Kolb NA, Trevino CR, Waheed W, Sobhani F, Landry KK, Thomas AA, et al. Neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve. 2018. \nhttps:\/\/doi.org\/10.1002\/mus.26070\n\n.","journal-title":"Muscle & Nerve"},{"issue":"1","key":"774_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019;7(1):134.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"774_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/pds.1399","volume":"16","author":"WN Kelly","year":"2007","unstructured":"Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards IR, Fernandez AM, et al. Guidelines for submitting adverse event reports for publication. Pharmacoepidemiol Drug Saf. 2007;16(5):581\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"774_CR21","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.semarthrit.2018.05.006","volume":"48","author":"M Shah","year":"2019","unstructured":"Shah M, Tayar JH, Abdel-Wahab N, Suarez-Almazor ME. Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum. 2019;48(4):736\u201340.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"774_CR22","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/cas.12961","volume":"107","author":"T Kimura","year":"2016","unstructured":"Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016;107(7):1055\u20138.","journal-title":"Cancer Sci"},{"issue":"1","key":"774_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/jjco\/hyv158","volume":"46","author":"T Shirai","year":"2016","unstructured":"Shirai T, Sano T, Kamijo F, Saito N, Miyake T, Kodaira M, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol. 2016;46(1):86\u20138.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"774_CR24","first-page":"59","volume":"43","author":"R Tanaka","year":"2017","unstructured":"Tanaka R, Sunada Y, Wataru F. Successful reinstitution of nivolumab in combination with corticosteroids for metastatic malignant melanoma with myasthenia gravis as an immune-related adverse event. Kawasaki Med J. 2017;43(2):59\u201361.","journal-title":"Kawasaki Med J"},{"issue":"3","key":"774_CR25","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1159\/000479958","volume":"10","author":"Y Fukasawa","year":"2017","unstructured":"Fukasawa Y, Sasaki K, Natsume M, Nakashima M, Ota S, Watanabe K, et al. Nivolumab-induced myocarditis concomitant with myasthenia gravis. Case Rep Oncol. 2017;10(3):809\u201312.","journal-title":"Case Rep Oncol"},{"issue":"11","key":"774_CR26","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017;89(11):1127\u201334.","journal-title":"Neurology."},{"issue":"2","key":"774_CR27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/CMR.0000000000000310","volume":"27","author":"BH Nguyen","year":"2017","unstructured":"Nguyen BH, Kuo J, Budiman A, Christie H, Ali S. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Melanoma Res. 2017;27(2):152\u20134.","journal-title":"Melanoma Res"},{"key":"774_CR28","doi-asserted-by":"crossref","unstructured":"Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve. 2019.","DOI":"10.1002\/mus.26689"},{"issue":"2","key":"774_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141\u20139.","journal-title":"Muscle Nerve"},{"issue":"6","key":"774_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/BF00315656","volume":"237","author":"R Mantegazza","year":"1990","unstructured":"Mantegazza R, Beghi E, Pareyson D, Antozzi C, Peluchetti D, Sghirlanzoni A, et al. A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol. 1990;237(6):339\u201344.","journal-title":"J Neurol"},{"issue":"11","key":"774_CR31","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/archneurol.2009.229","volume":"66","author":"Shigeaki Suzuki","year":"2009","unstructured":"Suzuki S, Utsugisawa K, Yoshikawa H, Motomura M, Matsubara S, Yokoyama K, et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol. 2009;66(11):1334\u20138.","journal-title":"Archives of Neurology"},{"issue":"1","key":"774_CR32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/mus.23882","volume":"49","author":"Emily Choi Decroos","year":"2013","unstructured":"Choi Decroos E, Hobson-Webb LD, Juel VC, Massey JM, Sanders DB. Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis? Muscle Nerve. 2014;49(1):30\u20134.","journal-title":"Muscle & Nerve"},{"issue":"3","key":"774_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/00019052-199806000-00007","volume":"11","author":"JA Aarli","year":"1998","unstructured":"Aarli JA. Inflammatory myopathy in myasthenia gravis. Curr Opin Neurol. 1998;11(3):233\u20134.","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"774_CR34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1600-0404.1984.tb00817.x","volume":"70","author":"H Hofstad","year":"1984","unstructured":"Hofstad H, Ohm OJ, Mork SJ, Aarli JA. Heart disease in myasthenia gravis. Acta Neurol Scand. 1984;70(3):176\u201384.","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"774_CR35","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.semarthrit.2018.05.004","volume":"48","author":"K Huang","year":"2019","unstructured":"Huang K, Shojania K, Chapman K, Amiri N, Dehghan N, Mezei M. Concurrent inflammatory myopathy and myasthenia gravis with or without thymic pathology: a case series and literature review. Semin Arthritis Rheum. 2019;48(4):745\u201351.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"774_CR36","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/archneur.62.3.442","volume":"62","author":"F Romi","year":"2005","unstructured":"Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol. 2005;62(3):442\u20136.","journal-title":"Arch Neurol"},{"issue":"27","key":"774_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007350","volume":"96","author":"YH Chen","year":"2017","unstructured":"Chen YH, Liu FC, Hsu CH, Chian CF. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: case report. Medicine (Baltimore). 2017;96(27):e7350.","journal-title":"Medicine (Baltimore)"},{"issue":"17","key":"774_CR38","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714\u201368.","journal-title":"J Clin Oncol"},{"issue":"3","key":"774_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","volume":"17","author":"JA Thompson","year":"2019","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. Management of Immunotherapy-Related Toxicities, version 1.2019. J Natl Compr Cancer Netw. 2019;17(3):255\u201389.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"774_CR40","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s13311-015-0398-y","volume":"13","author":"JT Guptill","year":"2016","unstructured":"Guptill JT, Soni M, Meriggioli MN. Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis. Neurotherapeutics. 2016;13(1):118\u201331.","journal-title":"Neurotherapeutics"},{"issue":"5","key":"774_CR41","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1212\/WNL.36.5.729","volume":"36","author":"RG Miller","year":"1986","unstructured":"Miller RG, Milner-Brown HS, Mirka A. Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology. 1986;36(5):729\u201332.","journal-title":"Neurology"},{"issue":"10","key":"774_CR42","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","volume":"13","author":"JS Bae","year":"2006","unstructured":"Bae JS, Go SM, Kim BJ. Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J Clin Neurosci. 2006;13(10):1006\u201310.","journal-title":"J Clin Neurosci"},{"issue":"6","key":"774_CR43","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"P Gajdos","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia gravis clinical study group. Ann Neurol. 1997;41(6):789\u201396.","journal-title":"Ann Neurol"},{"issue":"23","key":"774_CR44","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017\u201323.","journal-title":"Neurology"},{"issue":"11","key":"774_CR45","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","volume":"68","author":"L Zinman","year":"2007","unstructured":"Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68(11):837\u201341.","journal-title":"Neurology"},{"issue":"4","key":"774_CR46","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ane.12261","volume":"130","author":"S Hoffmann","year":"2014","unstructured":"Hoffmann S, Kohler S, Ziegler A, Meisel A. Glucocorticoids in myasthenia gravis - if, when, how, and how much? Acta Neurol Scand. 2014;130(4):211\u201321.","journal-title":"Acta Neurol Scand"},{"issue":"8","key":"774_CR47","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German neurological society. J Neurol. 2016;263(8):1473\u201394.","journal-title":"J Neurol"},{"key":"774_CR48","doi-asserted-by":"crossref","unstructured":"Centanni M, Moes D, Troconiz IF, Ciccolini J, van Hasselt JGC. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. Clin Pharmacokinet. 2019.","DOI":"10.1007\/s40262-019-00748-2"},{"issue":"10","key":"774_CR49","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1080\/17425255.2016.1216976","volume":"12","author":"TC Longoria","year":"2016","unstructured":"Longoria TC, Tewari KS. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016;12(10):1247\u201353.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"774_CR50","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000431036","volume":"44","author":"Marion I. Boldingh","year":"2015","unstructured":"Boldingh MI, Maniaol AH, Brunborg C, Dekker L, Heldal AT, Lipka AF, et al. Geographical Distribution of Myasthenia Gravis in Northern Europe--Results from a Population-Based Study from Two Countries. Neuroepidemiology. 2015;44(4):221-31.","journal-title":"Neuroepidemiology"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0774-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0774-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0774-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:46:03Z","timestamp":1601055963000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0774-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["774"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0774-y","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"14 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center. IRB number: PA15\u20130071.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"319"}}